Contact: Phil Kearney, CEO

Axelia Oncology is a biotechnology company that is developing a novel innate immunomodulator with a district mechanism of action for the treatment of solid tumours.  It is based on research that has come out of the Department of Immunology / Peter Doherty Institute for Infection and Immunity at the University of Melbourne.